Gossamer Bio, Inc. (NASDAQ:GOSS) has been given an average rating of “Buy” by the six ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $22.80.
GOSS has been the topic of several research analyst reports. Zacks Investment Research lowered Gossamer Bio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 12th. HC Wainwright reissued a “buy” rating and set a $24.00 target price (up previously from $15.00) on shares of Gossamer Bio in a research report on Thursday, December 17th.
Shares of NASDAQ GOSS traded down $0.85 during midday trading on Tuesday, hitting $10.09. 1,206,427 shares of the company’s stock were exchanged, compared to its average volume of 631,664. The company has a debt-to-equity ratio of 0.46, a current ratio of 17.36 and a quick ratio of 17.36. Gossamer Bio has a twelve month low of $7.52 and a twelve month high of $16.79. The company has a market cap of $766.11 million, a PE ratio of -3.07 and a beta of 1.34. The firm’s fifty day simple moving average is $10.44 and its 200-day simple moving average is $10.92.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial.
Further Reading: What’s a Black Swan?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.